Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.49
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Dr. Reddy’s Q4 & FY15 Financial Results
May 12, 2015 7:21 AM EDT
Q4 FY15 Revenues at Rs. 38.7 billion
(YoY growth of 11%)
Q4 FY15 EBITDA at Rs. 8.1 billion
(21% of revenues)
FY15 Revenues at Rs. 148.2 billion
(YoY growth of 12%)
FY15 EBITDA at Rs. 36.2 billion
(24% of revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY)Â (BSE: 500124)Â (NSE: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2015 under International Financial Reporting Standards (IFRS).
FY15: Key... More
